Single-cell DNA sequencing helped reveal the evolution of resistance against KRAS G12C inhibitors like sotorasib, which was approved earlier this year for directly inhibiting a mutation in the RAS family of oncogenes.
The researchers found that the secondary mutations they identified from bulk sequencing often co-occurred with the targeted mutation (KRAS G12C) in the drug-resistant cells (Nature, November 10, 2021).
These secondary mutations within the same cells were shown to circumvent the effect of target KRAS inhibitor therapy by upregulating other players in the pathway. The Tapestri platform allowed the research team to better understand how mutations emerge in individual cells, according to the firm.
Copyright © 2021 scienceboard.net